GC
LIVE

Serial Number

79241700

Owner

Green Cross Holdings Corporation

Attorney

Yoon S. Ham

Filing Date

May 17, 2018

Add to watchlist:

No watchlists yet
View on USPTO

GC Trademark

Serial Number: 79241700 • Registration: 6121018

GC is a trademark filed by Green Cross Holdings Corporation on May 17, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Green Cross Holdings Corporation (24 trademarks)

107, Ihyeon-ro 30beon-gil, Giheung-gu,
Yongin-si, Gyeonggi-do 16924 , KR

Entity Type: 03

Trademark Details

Filing Date

May 17, 2018

Registration Date

August 11, 2020

Published for Opposition

May 26, 2020

Goods & Services

Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Medicines for humans, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; medicated plasters; vaccines; biological preparations for medical or veterinary purposes, namely, biological preparations used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; biological preparations for medical or veterinary purposes, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors

Retail store services featuring pharmaceutical preparations for the treatment of cells; retail store services featuring medical instruments; retail store services featuring medical apparatus; retail store services featuring biological preparations for medical purposes; retail store services featuring medical genetic analyzer; retail and wholesale store services featuring pharmaceutical preparations; import-export agency services; retail store services featuring electromedical diagnostic instruments; wholesale store services featuring pharmaceutical preparations for the treatment of cells; wholesale store services featuring medical instruments; wholesale store services featuring medical apparatus; wholesale store services featuring biological preparations for medical purposes; wholesale store services featuring medical genetic analyzer; wholesale store services featuring electromedical diagnostic instruments; all the foregoing excluding services in the field of industrial, institutional, commercial and janitorial equipment and supplies

Medical services, namely, the removal, treatment and processing of human blood, umbilical cord blood, human cells, stem cells and bone marrow for medical preventive, diagnostic and treatment purposes; medical examination services; health clinic services, namely, medical clinics; analysis of human tissues for medical diagnosis purposes and treatment; medical consultancy for selecting appropriate medicines; human tissue bank services; medical services, namely, clinical pathology examination; cord blood bank services; health center services; medical and pharmaceutical consultancy; medical and health care services; pharmacy services, namely, dispensing of pharmaceuticals; consultancy and information services relating to the dispensing of pharmaceutical products; dispensing of pharmaceuticals; preparation and dispensing of medications; information services relating to utilization of medical products in connection with the provision of medical services; medical and health services relating to DNA, genetics and genetic testing; managed health care services

Medical apparatus and instruments for use in performing biopsies; medical testing apparatus for medical purposes, namely, medical apparatus for testing DNA and RNA samples; medical diagnostic apparatus and instruments for immunodiagnosis and molecular diagnosis; electromedical diagnostic instruments for immunodiagnosis and molecular diagnosis; apparatus for use in medical analysis, namely, medical apparatus for blood test; medical health signal measuring instruments for monitoring vital signs; wireless bio-signal measuring instruments for medical purposes, namely, biofeedback sensors; precision sensors for medical use, namely, heart rhythm sensors, respiratory sensors and biofeedback sensors; laser machining tools for medical use, namely, lasers for surgical and medical use; genetic testing apparatus, namely, apparatus for DNA and RNA testing for medical purposes

Research and development of vaccines and medicines; conducting clinical studies of medicines for medical research purposes; clinical research in the nature of performing biopsies for medical research; product research and development of medical products; conducting technical project studies, namely, engineering services in the nature of technical project planning and design engineering of medical products; testing, inspection or research of pharmaceuticals; scientific research relating to biology; scientific research in the field of genetic engineering; research and development of technology for biotechnology; scientific research in the fields of biomedicine; laboratory research in the field of biology; product development of cell therapy products; drug discovery services; research and development in the pharmaceutical and biotechnology fields; scientific research in the field of gene analysis; medical studies, namely, medical laboratory services; research and development of technology for medicinal chemical manufacturing; medical research services relating to clinical data

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Aug 11, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 26, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 3, 2020 FICS
FINAL DISPOSITION PROCESSED
Dec 3, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 11, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Aug 11, 2020 R.PR
NOTIFICATION PROCESSED BY IB
Jun 12, 2020 GPNX
POST PUBLICATION AMENDMENT - ENTERED
Jun 12, 2020 CHPB
ASSIGNED TO PETITION STAFF
Jun 11, 2020 APET
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 26, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 26, 2020 PUBO
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 11, 2020 EPPA
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 6, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 6, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 6, 2020 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 21, 2020 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 13, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 13, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 13, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 13, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 13, 2020 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 2, 2020 ZZZX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 20, 2020 OPNX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Mar 10, 2020 PBCR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 4, 2020 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 4, 2020 OPNR
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 26, 2020 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 19, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 19, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 19, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 19, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 19, 2020 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Feb 19, 2020 ZZZX
WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST
Feb 19, 2020 ISMR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Jan 10, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 25, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 25, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 25, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 10, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 6, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 30, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jul 30, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jul 30, 2019 CNRT
LETTER OF PROTEST EVIDENCE FORWARDED
Jul 23, 2019 LOPT
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 30, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
May 30, 2019 GNSL
SUSPENSION LETTER WRITTEN
May 30, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 8, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2019 CRFA
ASSIGNED TO LIE
May 8, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 1, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 22, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 22, 2019 REAP
REFUSAL PROCESSED BY IB
Nov 24, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 2, 2018 RFCS
REFUSAL PROCESSED BY MPU
Nov 2, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 19, 2018 RFCR
NON-FINAL ACTION WRITTEN
Oct 18, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 13, 2018 MAFR
ASSIGNED TO EXAMINER
Oct 9, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 9, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 27, 2018 REPR